Tadocizumab
From Wikipedia, the free encyclopedia
Tadocizumab is a humanized monoclonal antibody that acts on the cardiovascular system.[1] It binds to integrin αIIbβ3, a fibrinogen and fibronectin receptor found on platelets.[2]
The drug is designed for the treatment of patients undergoing percutaneous coronary interventions. It was developed by Yamanōchi Pharma America, Inc.[1]
[edit] References
- ^ a b Statement On A Nonproprietary Name Adopted By The USAN Council - Tadocizumab, American Medical Association.
- ^ Molecular cell biology. Lodish, Harvey F. 5. ed. : – New York : W. H. Freeman and Co., 2003, 973 s. b ill. ISBN 0-7167-4366-3
(what is this?) (verify)
